Navigation Links
ECNP expresses concern at AstraZeneca neuroscience pull-out
Date:2/6/2012

The European College of Neuropsychopharmacology expresses its deep concern at the recently announced withdrawal by AstraZeneca from neuroscience drug research. AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

"Disorders of the brain are Europe's pre-eminent health care concern of the future," says ECNP president, Joseph Zohar, professor of psychiatry at Tel Aviv University. "Medications, properly targeted, are in almost all cases the key to effective treatment. To have a major player like AstraZeneca, with an outstanding history of innovation and development in disorders of the brain, pull out of the field in this way will inevitably affect Europeans' access to high-quality medications in the future. This is not good news for patients."

Research sponsored by ECNP shows that more than a third of all Europeans experience some form of mental disorder in any given year, at a total cost to the region of some 800 billion per annum. The direct medical costs of these disorders constitute almost a quarter of the European Union's total health care expenditure, with indirect costs from work absences to enforced early retirement almost twice as much again. The social and emotional costs are incalculable.

AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies, including GlaxoSmithKline, Pfizer, Merck, Sanofi and Novartis, who have all significantly downsized their neuroscience commitment. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

"Neuroscience has long been one of Europe's outstanding scientific strengths," says ECNP secretary, Sven Ove gren, professor of neuroscience at Sweden's Karolinska Institutet. "The loss of hundreds of research positions in the field is an enormous blow. Coming on top of similar closures at almost all of Europe's big pharma companies, it's a very worrying development. What's now urgently needed is united action from all those interested in Europe's neuroscientific future to ensure that the region's neuroscience research base of which pharma is an indispensible part does not suffer permanent and possibly irreversible damage."


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
43-140-55734
European College of Neuropsychopharmacology
Source:Eurekalert

Related medicine news :

1. Supportive of intent of ACO proposed rule, ACP expresses concern
2. IHRSA Expresses Its Ardent Support of America's First-Ever National Physical Activity Plan and Accepts Role as Co-Chair of Implementation Sub-Committee
3. U.S. African Chamber of Commerce President Expresses Concern over Health Care Bill
4. Cases of Tamiflu-Resistant Flu Concern Experts
5. Women should still be concerned about hormone replacement therapy, say McMaster researchers
6. Buildup of Newer Flame Retardants Concerns Scientists
7. Potential concern about drugs in clinical trial
8. Group sex among adolescents a public health concern, new study says
9. 15 new conservation concerns
10. Concerns about teen sexting overblown, according to new UNH research
11. Internists address dual concerns of privacy and protection of health data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... annual awards, now in their 12th year, are among the most prestigious in radiology ... 2016, the awards were retooled to recognize achievements in both large budget (over $5,000) ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... ... ... The law firm of Enea, Scanlan & Sirignano, LLP, with ... C. Enea has joined the firm as an associate attorney. Ms. Enea, who previously ... law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha A. Lyons, ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social ... devotional journal chronicling the writer’s path toward true communion with God. “Finding Christ ... #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a follower of ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization ... could be four million Zika-related cases in the Americas within the next year. Lyme ... cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... YORK , March 24, 2017 ... ... a leading publisher of cannabis market research, the legal cannabis ... percent CAGR through 2021, despite conflicting signals from the current ... points out that the two biggest drivers of growth in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 ... market of deep learning solutions within the healthcare domain. Primarily driven ... a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... -- Today Stock-Callers.com have issued research reports on ... (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. (NYSE: ... These companies are part of the Healthcare sector, which gave ... rd , 2017, with the NYSE Health Care Index declining ... in the S&P 500 were down about 0.4% as a ...
Breaking Medicine Technology: